These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 19925429)

  • 21. Pharmacogenomic genome-wide association studies: lessons learned thus far.
    Crowley JJ; Sullivan PF; McLeod HL
    Pharmacogenomics; 2009 Feb; 10(2):161-3. PubMed ID: 19207016
    [No Abstract]   [Full Text] [Related]  

  • 22. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.
    Zheng D; Chen Y; Gao C; Wei Y; Cao G; Lu N; Hou Y; Jiang X; Wang J
    Cancer Biol Ther; 2014; 15(11):1542-51. PubMed ID: 25482940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines.
    Stark AL; Zhang W; Mi S; Duan S; O'Donnell PH; Huang RS; Dolan ME
    Pharmacogenomics J; 2010 Dec; 10(6):505-12. PubMed ID: 20142840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenomic characterization of US FDA-approved cytotoxic drugs.
    Peters EJ; Motsinger-Reif A; Havener TM; Everitt L; Hardison NE; Watson VG; Wagner M; Richards KL; Province MA; McLeod HL
    Pharmacogenomics; 2011 Oct; 12(10):1407-15. PubMed ID: 22008047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of genomic information to optimize cancer chemotherapy.
    Innocenti F; Cox NJ; Dolan ME
    Semin Oncol; 2011 Apr; 38(2):186-95. PubMed ID: 21421109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using genome-wide association studies to identify genes important in serious adverse drug reactions.
    Daly AK
    Annu Rev Pharmacol Toxicol; 2012; 52():21-35. PubMed ID: 21819236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenomics of sex difference in chemotherapeutic toxicity.
    Wang J; Huang Y
    Curr Drug Discov Technol; 2007 Jun; 4(1):59-68. PubMed ID: 17630929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients.
    Mhandire DZ; Goey AKL
    Mol Diagn Ther; 2022 Mar; 26(2):137-151. PubMed ID: 35113367
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetics and pharmacogenomics of anticancer agents.
    Huang RS; Ratain MJ
    CA Cancer J Clin; 2009; 59(1):42-55. PubMed ID: 19147868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenetic content of commercial genome-wide genotyping arrays.
    Lemieux Perreault LP; Zaïd N; Cameron M; Mongrain I; Dubé MP
    Pharmacogenomics; 2018 Oct; 19(15):1159-1167. PubMed ID: 30272537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenomics: the promise of personalized medicine.
    Mancinelli L; Cronin M; Sadée W
    AAPS PharmSci; 2000; 2(1):E4. PubMed ID: 11741220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-throughput framework for genetic analyses of adverse drug reactions using electronic health records.
    Zheng NS; Stone CA; Jiang L; Shaffer CM; Kerchberger VE; Chung CP; Feng Q; Cox NJ; Stein CM; Roden DM; Denny JC; Phillips EJ; Wei WQ
    PLoS Genet; 2021 Jun; 17(6):e1009593. PubMed ID: 34061827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical association between pharmacogenomics and adverse drug reactions.
    Zhou ZW; Chen XW; Sneed KB; Yang YX; Zhang X; He ZX; Chow K; Yang T; Duan W; Zhou SF
    Drugs; 2015 Apr; 75(6):589-631. PubMed ID: 25895462
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacogenetics and prediction of side effects of drugs].
    Harrak M; Khabbal Y; Amarti A; El Hassouni M; Ouldim K
    Ann Biol Clin (Paris); 2014; 72(4):405-12. PubMed ID: 25119798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Approaches to the discovery of pharmacogenomic markers in oncology: 2000-2010-2020.
    Huang RS; Dolan ME
    Pharmacogenomics; 2010 Apr; 11(4):471-4. PubMed ID: 20350124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue-specific genetic features inform prediction of drug side effects in clinical trials.
    Duffy Á; Verbanck M; Dobbyn A; Won HH; Rein JL; Forrest IS; Nadkarni G; Rocheleau G; Do R
    Sci Adv; 2020 Sep; 6(37):. PubMed ID: 32917698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GPEdit: the genetic and pharmacogenomic landscape of A-to-I RNA editing in cancers.
    Ruan H; Li Q; Liu Y; Liu Y; Lussier C; Diao L; Han L
    Nucleic Acids Res; 2022 Jan; 50(D1):D1231-D1237. PubMed ID: 34534336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germline genetic testing to predict drug response and toxicity in oncology--reality or fiction?
    Soh TI; Yong WP
    Ann Acad Med Singap; 2011 Aug; 40(8):350-5. PubMed ID: 22065000
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation.
    Wheeler HE; Dolan ME
    Pharmacogenomics; 2012 Jan; 13(1):55-70. PubMed ID: 22176622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacogenomics in cancer therapy: is host genome variability important?
    Petros WP; Evans WE
    Trends Pharmacol Sci; 2004 Sep; 25(9):457-64. PubMed ID: 15559247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.